IOVA Relative Valuation
IOVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IOVA is overvalued; if below, it's undervalued.
Historical Valuation
Iovance Biotherapeutics Inc (IOVA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.13. The fair price of Iovance Biotherapeutics Inc (IOVA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.20
Fair
-3.64
PE
1Y
3Y
5Y
Trailing
Forward
-3.33
EV/EBITDA
Iovance Biotherapeutics Inc. (IOVA) has a current EV/EBITDA of -3.33. The 5-year average EV/EBITDA is -6.01. The thresholds are as follows: Strongly Undervalued below -14.68, Undervalued between -14.68 and -10.35, Fairly Valued between -1.68 and -10.35, Overvalued between -1.68 and 2.65, and Strongly Overvalued above 2.65. The current Forward EV/EBITDA of -3.33 falls within the Historic Trend Line -Fairly Valued range.
-2.56
EV/EBIT
Iovance Biotherapeutics Inc. (IOVA) has a current EV/EBIT of -2.56. The 5-year average EV/EBIT is -5.75. The thresholds are as follows: Strongly Undervalued below -14.43, Undervalued between -14.43 and -10.09, Fairly Valued between -1.41 and -10.09, Overvalued between -1.41 and 2.92, and Strongly Overvalued above 2.92. The current Forward EV/EBIT of -2.56 falls within the Historic Trend Line -Fairly Valued range.
2.36
PS
Iovance Biotherapeutics Inc. (IOVA) has a current PS of 2.36. The 5-year average PS is 42.91. The thresholds are as follows: Strongly Undervalued below -213.42, Undervalued between -213.42 and -85.25, Fairly Valued between 171.08 and -85.25, Overvalued between 171.08 and 299.25, and Strongly Overvalued above 299.25. The current Forward PS of 2.36 falls within the Historic Trend Line -Fairly Valued range.
-3.42
P/OCF
Iovance Biotherapeutics Inc. (IOVA) has a current P/OCF of -3.42. The 5-year average P/OCF is -9.43. The thresholds are as follows: Strongly Undervalued below -22.33, Undervalued between -22.33 and -15.88, Fairly Valued between -2.99 and -15.88, Overvalued between -2.99 and 3.46, and Strongly Overvalued above 3.46. The current Forward P/OCF of -3.42 falls within the Historic Trend Line -Fairly Valued range.
-5.87
P/FCF
Iovance Biotherapeutics Inc. (IOVA) has a current P/FCF of -5.87. The 5-year average P/FCF is -8.88. The thresholds are as follows: Strongly Undervalued below -20.01, Undervalued between -20.01 and -14.44, Fairly Valued between -3.32 and -14.44, Overvalued between -3.32 and 2.24, and Strongly Overvalued above 2.24. The current Forward P/FCF of -5.87 falls within the Historic Trend Line -Fairly Valued range.
Iovance Biotherapeutics Inc (IOVA) has a current Price-to-Book (P/B) ratio of 1.21. Compared to its 3-year average P/B ratio of 2.70 , the current P/B ratio is approximately -55.22% higher. Relative to its 5-year average P/B ratio of 3.72, the current P/B ratio is about -67.51% higher. Iovance Biotherapeutics Inc (IOVA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -25.24%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -19.45% , the current FCF yield is about -100.00% lower.
1.21
P/B
Median3y
2.70
Median5y
3.72
-40.10
FCF Yield
Median3y
-25.24
Median5y
-19.45
Competitors Valuation Multiple
The average P/S ratio for IOVA's competitors is 0.00, providing a benchmark for relative valuation. Iovance Biotherapeutics Inc Corp (IOVA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 15.20%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IOVA decreased by 70.27% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 58.56M to 67.46M.
The secondary factor is the Margin Expansion, contributed -5.18%to the performance.
Overall, the performance of IOVA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Iovance Biotherapeutics Inc (IOVA) currently overvalued or undervalued?
What is Iovance Biotherapeutics Inc (IOVA) fair value?
How does IOVA's valuation metrics compare to the industry average?
What is the current P/B ratio for Iovance Biotherapeutics Inc (IOVA) as of Dec 05 2025?
What is the current FCF Yield for Iovance Biotherapeutics Inc (IOVA) as of Dec 05 2025?
What is the current Forward P/E ratio for Iovance Biotherapeutics Inc (IOVA) as of Dec 05 2025?